Screening&Fluidics’ Post

Spread the word

Novel electrical impedance #technique enhances drug testing for #cardiac safety: When developing new #drugs, understanding their effects on ion channels in the body, such as the human ether-a-go-go-related gene (hERG) ion channel found in #neurons and heart muscle cells, is critical. Blocking hERG channels can disrupt normal heart rhythm, potentially leading to a fatal condition known as torsade de pointes. Current methods for assessing these effects typically involve invasive procedures like patch-clamp #techniques or fluorescence microscopy. These methods alter cell properties and may affect measurement accuracy, requiring specialized equipment and expertise, which increases cost and complexity. To address these challenges, researchers led by Daisuke Kawashima, an Assistant Professor at the Graduate School of Engineering at Chiba University, have proposed a novel, non-invasive method for real-time evaluation of drug effects on hERG channels. They developed a printed circuit board (PCB) sensor integrating electrical impedance tomography (EIT) with extracellular voltage activation (EVA). EIT measures impedance changes caused by ion movement, offering spatial information about extracellular ion distribution. EVA involves applying controlled extracellular voltages to induce changes in ion channel activity. This integrated approach allows researchers to non-invasively activate hERG channels and monitor real-time ion flow changes in response to drug exposure. The study was published in the journal Lab on A Chip on May 23, 2024. It included contributions from Assistant Professor Songshi Li and Professor Masahiro Takei from the Graduate School of Engineering, Chiba University, along with Associate Professor Satoshi Ogasawara and Professor Takeshi Murata from the Graduate School of Science, Chiba University. "This imaging technique is expected to serve as a new measurement and evaluation technology platform for medical and drug discovery," says Dr. Kawashima. The EIT–EVA PCB sensor is made from non-conductive epoxy glass fiber (FR-4 TG130) and measures 100 mm × 70 mm × 1.6 mm. It has 16 electrodes for EIT measurement arranged around a central activation electrode for EVA activation. Here's how it works: The cells under investigation for drug effects on ion channels are placed on the sensor. A step voltage is applied to the activation electrode, which changes potential distribution in the extracellular medium surrounding the cells. This change affects the cell membrane potential, activating voltage-gated ion channels like the hERG channels. When these channels open, potassium ions move out of the cells, changing the extracellular resistance, which is measured by the EIT system. The drug's effect on the ion channel is then observed by monitoring changes in extracellular conductivity. If the hERG channels are not blocked by the drug, the concentration of potassium ions outside the cells increases quickly.

Do radiopharma companies need to hire people with Radiopharma backgrounds? Ben Pais shares the subtleties and advantages of hiring someone with a radiopharma background for clinical research. 👉Radiopharma people need to think about the logisitics and supply more than say small molecule/mAb, this influences the trial design. 👉Reduced site selection: A site must have access to radiopharmacies and radiologist/Nuclear physicians - this greatly limits the number of available sites and patients. 👉Big picture thinking: Navigating technical hurdles in PII/PIII before they happen. For example, where do you store Urine samples? They are now technically radioactive samples. Small things like this cost companies days, weeks or years on their trials. Having the right experts in place can stop problems before they happen. That is why Ben Pais is such an asset to companies like Aricieum. Ultimately BEHAVIOURS are more important than KNOWLEDGE - but if you have someone with both, this can be gamechanging when running your trials. -- 👉 Need help finding specialist skills for your trials? Contact me today. 👉 For the full Episode, search Dose of Reality Ben Pais :)

𝐋𝐢𝐩𝐨𝐬𝐨𝐦𝐞𝐬 𝐯𝐬. 𝐏𝐫𝐨𝐛𝐢𝐨𝐬𝐨𝐦𝐞𝐬: 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲? Liposomal technology is a specialized branch of nanotechnology, which has allowed to improve many of the drawbacks and limitations of traditional drug therapy. Read More: https://lnkd.in/dwCEUdHC #DrugDelivery #Nanomedicine #Liposomes #Probiosomes #FutureofMedicine #SSE

𝐏𝐢𝐞𝐳𝐨𝐞𝐥𝐞𝐜𝐭𝐫𝐢𝐜 𝐁𝐢𝐨𝐬𝐞𝐧𝐬𝐨𝐫𝐬 : 𝐅𝐮𝐭𝐮𝐫𝐞 𝐒𝐜𝐨𝐩𝐞 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐏𝐃𝐅@ https://lnkd.in/dUjByEm9 Piezoelectric biosensors represent a cutting-edge technology that integrates the principles of piezoelectricity with biosensing capabilities. These sensors convert biological interactions, such as the binding of biomolecules, into measurable electrical signals. Their precision, sensitivity, and real-time monitoring capabilities make them invaluable tools in various biomedical applications. Piezoelectric biosensors find extensive use in medical diagnostics for the detection of biomarkers associated with various diseases, including cancer, infectious diseases, and autoimmune disorders. Piezoelectric biosensors play a crucial role in drug development by enabling the real-time monitoring of molecular interactions. This aids in the study of binding kinetics and drug-receptor interactions. Piezoelectric biosensors exhibit high sensitivity, allowing for the detection of target molecules at low concentrations. This is particularly advantageous in medical diagnostics and research applications. Piezoelectric biosensors often enable label-free detection, eliminating the need for additional labels or tags on biomolecules. This simplifies the assay procedure and reduces potential interferences. Piezoelectric biosensors exemplify the synergy between materials science and biotechnology, offering a powerful platform for the precise detection of biomolecules. As research and innovation progress, these biosensors are poised to play an increasingly pivotal role in advancing diagnostics, environmental monitoring, and biotechnological research. 🌐⚙️ Application: Medical Automotive Tools Electronics Other Manufacturers covered in this report: Abbott Point of Care, ACON Laboratories, Bayer, LifeScan, LifeSensors, Inc, Medtronic, F. Hoffmann-La Roche Ltd, Pharmaco-Kinesis Corporation, Siemens, Universal Biosensors. #biosensors #piezoelectricity #biomedicaldetection #diagnostics #materialsinnovation

Live Cell Imaging Market Size, Share & Trends Analysis Report By Type (Cell Analyzers, Accessories, Consumables, Instruments, Microscopes, Standalone Systems, Reagents, Assay Kit), By Technology (Fluorescence Recovery after Photobleaching (FRAP), High-content screening (HCS), Time-lapse Microscopy, Fluorescence Resonance Energy Transfer (FRET)), By End-Users (Pharmaceutical & Biotechnology Companies, Academic & Research Institute), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 Global Live Cell Imaging Market size was valued at USD 1841.5 Million in 2021 and is projected to reach USD 3241.4 Million by 2028, growing at a CAGR of 8.94% from 2021 to 2028 𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. Don't miss out on this opportunity to stay informed about the latest trends in the Industry. 📚𝐆𝐞𝐭 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐭 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐏𝐫𝐢𝐜𝐞:📝👇https://lnkd.in/duSZB4nx   📚𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐨𝐜𝐮𝐬𝐞𝐝 𝐎𝐧 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬: Araceli Biosciences BioTek Instruments Bruker Bruker BioSpin Bruker Daltonics Bruker Nano Surfaces & Metrology ChromoTek Confocal.nl Cytek Biosciences CytoSMART Technologies Danaher Life Sciences Elveflow Microfluidics | an Elvesys brand Etaluma, Inc. GE HealthCare GENOSKIN Illumina ibidi GmbH 3i - Intelligent Imaging Innovations Interherence Nanolive SA Nexcelom Noble Life Sciences Inc Okolab Oxford Instruments plc PerkinElmer Phase Holographic Imaging Phasefocus Ramcon Sartorius Teledyne Photometrics Thermo Fisher Scientific Thistle Scientific Thrive Bioscience, Inc. TOMOCUBE, INC. Vala Sciences Yokogawa Life Science ZEISS Microscopy #LiveCellImaging #Intellectualmarketinsightresearch #Marketresearchreports #Size #Share #Trends #Growth #Opportunity #Outlook #Forecast #Covid19 #Segments #KeyPlayers #RegionsOutlook #GrowthPotential #PriceTrends #CompetitiveMarket #Forecast #2022To2028

Microfluidics and Lab-on-a-Chip Technology| srihabensh | snsinstitutions #snsinstitutions #SNSdesignthinkers #designthinking Microfluidics and Lab-on-a-Chip technology have revolutionized various fields, including biotechnology, medicine, chemistry, and environmental science. These technologies enable the precise manipulation of small volumes of fluids on a microscale, offering numerous advantages such as increased sensitivity, reduced sample and reagent consumption, faster analysis times, and the integration of multiple laboratory functions onto a single chip. In microfluidics, fluids flow through microchannels with dimensions typically on the order of micrometers. Lab-on-a-Chip devices leverage microfluidic principles to miniaturize and automate laboratory processes, allowing for the development of portable, cost-effective, and user-friendly analytical tools. Applications of microfluidics and Lab-on-a-Chip technology span a wide range of areas: 1. **Biomedical Diagnostics**: Lab-on-a-Chip devices can perform various diagnostic tests, including blood analysis, DNA sequencing, pathogen detection, and point-of-care testing. These devices offer rapid results, which is crucial for timely medical interventions. 2. **Drug Discovery and Development**: Microfluidic platforms facilitate high-throughput screening of drug candidates, enabling researchers to test multiple compounds simultaneously while conserving precious resources. These systems also support the study of drug metabolism, pharmacokinetics, and personalized medicine. 3. **Analytical Chemistry**: Microfluidic devices are employed in chemical analysis for tasks such as sample preparation, chromatography, and spectroscopy. They offer improved sensitivity, resolution, and throughput compared to traditional benchtop techniques. 4. **Environmental Monitoring**: Lab-on-a-Chip technology enables on-site analysis of environmental samples for pollutants, pathogens, and contaminants. These devices contribute to real-time monitoring efforts and early detection of environmental hazards. 5. **Point-of-Care Testing (POCT)**: Lab-on-a-Chip devices are well-suited for POCT applications due to their portability, rapid analysis times, and minimal sample requirements. They are used for diagnosing diseases, monitoring health parameters, and managing chronic conditions outside of traditional laboratory settings. 6. **Single-Cell Analysis**: Microfluidic platforms enable the isolation, manipulation, and analysis of individual cells, offering insights into cellular heterogeneity, cell-cell interactions, and rare cell populations. These techniques have implications for cancer research, immunology, and developmental biology. Overall, microfluidics and Lab-on-a-Chip technology continue to drive innovation in research, healthcare, and industry by providing scalable, efficient, and cost-effective solutions to complex analytical challenges.

In the late 1980s, some cancer patients treated with the Therac-25 radiation therapy machine died from radiation poisoning due to overdoses. Investigations found that the root cause was a mix of hardware and software issues. As explained by Nancy Leveson in "Safeware," one incident occurred because a technician edited treatment data in under eight seconds, coinciding with the magnetic locks' engagement time, creating a critical vulnerability. The speed of input is a very subtle variable. The way users interact with the system is always a variable, of course, but the speed of input, and the fact that there was an important threshold at the eight-second mark, is quite subtle. Yet it’s also a potentially common situation: power users can generally manipulate systems with astonishing fluency. Using keyboard shortcuts and with lightning fast typing speeds, they may be able to enter data so quickly that they get ahead of the system. In response, the system may exhibit interesting behavior, such as unexpected errors or, as in this case, catastrophic failure. Leveson found that every 256th time the Therac-25 setup routine ran, it bypassed a crucial safety check, leading to potentially fatal malfunctions. This periodic behavior meant the system was vulnerable at specific intervals, like the 256th and 512th startups.

𝗡𝗲𝗮𝗿 𝗜𝗻𝗳𝗿𝗮𝗿𝗲𝗱 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗚𝗿𝗼𝘄 𝘁𝗼 $1.6 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/dmsCt9fi The global near-infrared imaging market in terms of revenue was estimated to be worth $1.0 billion in 2023 and is poised to reach $1.6 billion by 2028, growing at a CAGR of 10.2% from 2023 to 2028. Stryker KARL STORZ ZEISS Medical Technology Leica Microsystems Olympus Corporation SHIMADZU CORPORATION PerkinElmer, Inc. LI-COR Biotechnology Hamamatsu Photonics Quest Medical Imaging Sigma-Aldrich Teledyne Princeton Instruments Thermo Fisher Scientific FLUOPTICS Part of Getinge Medtronic Cayman Chemical MP Biomedicals CRYSTA-LYN CHEMICAL COMPANY, INC Gowerlabs NIRx Medical Technologies Biotium Tokyo Chemical Industry (India) Pvt. Ltd AAT Bioquest

🔬 Exciting Growth Ahead: Label-Free Detection Market Analysis 📥 Download Complete PDF: https://lnkd.in/dGEv_EnD The label-free detection market is set for remarkable expansion, with projections showing growth from $515M (2024) to $747M by 2029, achieving a robust 7.7% CAGR. Key Market Segments: 🔹 Instruments 🔹 Consumables (Biosensor Chips & Microplates) 🔹 Software Solutions 🔹 Specialized Services Driving Technologies: - Surface Plasmon Resonance (SPR) - Differential Scanning Calorimetry (DSC) What's fueling this growth? The increasing demand for label-free detection in drug discovery, particularly in lead generation, is revolutionizing how we approach molecular interactions and binding studies. 💡 Why This Matters: - More accurate results - Reduced experiment complexity - Cost-effective drug development - Real-time monitoring capabilities 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Danaher Corporation (US), Sartorius AG (Germany), Waters Corporation (US), Agilent Technologies, Inc. (US), Corning Incorporated (US), REVVITY, INC. (US), Ametek, Inc. (US), Horiba, Ltd. (Japan), Spectris (UK), Shimadzu Corporation (Japan), Hitachi High-Tech Corporation (Japan), Attana AB (Sweden), Bruker Corporation (US), Bio-Rad Laboratories (US), ENDRESS+HAUSER Group Services AG (Switzerland), Becton, Dickinson and Company (US), Nanotemper Technologies GmBH (Germany), Affinité Instruments (Canada), Biosensing Instrument (US) 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 uFluidix NANBIOSIS – ICTS Nick Holonyak, Jr. Micro and Nanotechnology Laboratory Aurox Ltd BioFluidica, Inc. Biosensing Instrument Inc Cellix CytoViva, Inc Echelon Biosciences Elveflow Microfluidics | an Elvesys brand Fluicell Fluxion.AI Fraunhofer Institute for Industrial Engineering IAO GSI Group Ibex Medical Analytics IDEX Health & Science, LLC Innosphere Kirkegaard & Perry Laboratories, Inc. (KPL) LabCyte by J-TEC Luminex Molecular Devices NanoEnTek, Inc. OptoGenTech GmbH Optofluidic Bioassay LLC Applied Materials – Picosun Plexxikon Inc. Quanterix Rogue Valley Microdevices, Inc. Sierra Sensors GmbH Spherotech, Inc Syntactx, Now Part of NAMSA Teknova Thermo Fisher Scientific XENOPORE CORP. Zeta Instruments, a KLA Company Bioinformatics Institute, A*STAR eBioscience OptiGene #BioTech #DrugDiscovery #MarketAnalysis #Innovation #PharmaTech #Research #LifeSciences